Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 200-Day Moving Average – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.77 and traded as low as $9.64. Astellas Pharma shares last traded at $9.71, with a volume of 89,294 shares changing hands.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market cap of $17.57 billion, a P/E ratio of -44.13 and a beta of 0.34. The company has a fifty day moving average price of $9.62 and a two-hundred day moving average price of $10.77.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. On average, sell-side analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.